Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.53 |
| ▸ | WDR5 | P61964 | 1/20 | 0.53 |
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SI | P14410 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | DDX3X | O00571 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468508 | 0.84 | ALDH1A1 (0.46) | MGAMGAASIPKMMGAM2 | |
| SCHEMBL15063762 | 0.81 | KDR (0.61) | MYCWDR5MGAMGAASI | |
| SCHEMBL5501424 | 0.78 | LMNA (0.54) | MYCWDR5MGAMGAASI | |
| SCHEMBL5150675 | 0.76 | ADORA1 (0.56) | ADORA1 | |
| SCHEMBL18513462 | 0.75 | KDR (0.38) | ALDH1A1MEN1KMT2AMAPTADORA1 | |
| SCHEMBL18513465 | 0.74 | KDR (0.66) | ADORA1 | |
| SCHEMBL12679739 | 0.73 | TSHR (0.52) | ALDH1A1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL14974336 | 0.72 | MAPT (0.47) | MYCWDR5MGAMGAASI | |
| SCHEMBL4419984 | 0.72 | MYC (0.51) | MYCWDR5MGAMGAASI | |
| SCHEMBL4898155 | 0.72 | MYC (0.45) | MYCWDR5ALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3184525-B1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXAMIDE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3184525-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CABOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2797916-B1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2797916-B1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN INC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-8969583-B2 | 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors | ALLERGAN, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969583-B2 | 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors | ALLERGAN, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| EP-2797916-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20130172353-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172353-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2013101954-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172353-A1 | 3-PHENYL-5-UREIDOISOTHIAZOLE-4-CARBOXIMIDE AND 3-AMINO-5-PHENYLISOTHIAZOLE DERIVATIVES AS KINASE INHIBITORS | REN, JAK2, FGFR1 | MYC 1576/4885WDR5 934/4885MGAM 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.